Efficacy of Oncolytic Herpes Simplex Virus T-VEC Combined with BET Inhibitors as an Innovative Therapy Approach for NUT Carcinoma

SIMPLE SUMMARY: Since T-VEC is already approved for treatment of melanoma, its promising efficacy shown here also for NUT carcinoma (NC) cell lines may create a rapid transition to individual treatments as well as clinical trials in NC patients. The idea of combining T-VEC immunotherapy with BET inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohnesorge, Paul V., Berchtold, Susanne, Beil, Julia, Haas, Simone A., Smirnow, Irina, Schenk, Andrea, French, Christopher A., Luong, Nhi M., Huang, Yeying, Fehrenbacher, Birgit, Schaller, Martin, Lauer, Ulrich M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179288/
https://www.ncbi.nlm.nih.gov/pubmed/35681742
http://dx.doi.org/10.3390/cancers14112761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179288/
https://www.ncbi.nlm.nih.gov/pubmed/35681742
http://dx.doi.org/10.3390/cancers14112761

Ejemplares similares